CollPlant Biotechnologies (CLGN) Enterprise Value (2017 - 2025)
CollPlant Biotechnologies' (CLGN) quarterly Enterprise Value came in at -$5.9 million in Q4 2025, up 51.06% YoY from -$3.9 million in Q4 2024, and up 49.18% on a QoQ basis from -$11.7 million in Q2 2025.
CollPlant Biotechnologies (CLGN) Enterprise Value (2017 - 2025) Analysis & Trends
CollPlant Biotechnologies (CLGN) has 9 years of Enterprise Value data on file, last reported at -$5.9 million in Q4 2025.
- Quarterly Enterprise Value rose 51.06% year-over-year to -$5.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$5.9 million (up 51.06% YoY) and the FY2025 annual result came in at -$5.9 million, up 51.06% from the prior year.
- Enterprise Value improved to -$5.9 million in Q4 2025, from -$11.7 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$5.9 million in Q4 2025 to a low of -$47.7 million in Q2 2021.
- A 5-year average of -$26.5 million and a median of -$26.8 million in 2023 frame the typical range for Enterprise Value.
- Annual changes were most pronounced in 2021 — Enterprise Value tumbled 1200.35% — and 2024, when it jumped 54.83%.
- Tracing CLGN's Enterprise Value over 5 years: stood at -$43.5 million in 2021, then surged by 31.33% to -$29.9 million in 2022, then grew by 9.94% to -$26.9 million in 2023, then jumped by 54.83% to -$12.2 million in 2024, then soared by 51.06% to -$5.9 million in 2025.
- The last three Enterprise Value figures came in at -$5.9 million (Q4 2025), -$11.7 million (Q2 2025), and -$12.2 million (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.41 Bn | 131.56 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 86.14 Bn | 78.15 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 65.52 Bn | 60.34 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 58.21 Bn | 53.07 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 42.15 Bn | 37.05 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 31.62 Bn | 28.31 Bn | 992.69 Mn | -3.31 Bn |
| 7 | BioNTech SE | 27.95 Bn | 9.56 Bn | 668.28 Mn | -18.39 Bn |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -1.16 Bn |
| 9 | Royalty Pharma | 27.30 Bn | 26.46 Bn | - | 2.12 Bn |
| 10 | CollPlant Biotechnologies | 4.23 Mn | 4.23 Mn | -243,000.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -5.95 Mn |
| Jun 30, 2025 | -11.71 Mn |
| Dec 31, 2024 | -12.16 Mn |
| Sep 30, 2024 | -15.37 Mn |
| Jun 30, 2024 | -19.16 Mn |
| Mar 31, 2024 | -26.67 Mn |
| Dec 31, 2023 | -26.92 Mn |
| Sep 30, 2023 | -28.98 Mn |
| Jun 30, 2023 | -22.45 Mn |
| Mar 31, 2023 | -29.86 Mn |
| Dec 31, 2022 | -29.89 Mn |
| Sep 30, 2022 | -32.81 Mn |
| Jun 30, 2022 | -36.50 Mn |
| Mar 31, 2022 | -41.29 Mn |
| Dec 31, 2021 | -43.53 Mn |
| Sep 30, 2021 | -25.76 Mn |
| Jun 30, 2021 | -47.75 Mn |
| Mar 31, 2021 | -19.91 Mn |
| Dec 31, 2020 | -3.53 Mn |
| Sep 30, 2020 | -5.04 Mn |